Bio-Path Investor Relations Material
Latest events
Q4 2023
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company that operates in the United States. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Bio-Path Holdings, Inc. was founded in 2007 and is headquartered in Bellaire, Texas.
Latest articles
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Ticker symbol
Country
đșđž United States